Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights

Rhea-AI Summary

Bristol Myers Squibb (NYSE:BMY) will host a virtual Investor Event on April 23, 2021, at 10:30 a.m. ET. The event will discuss data from the Phase 3 trials POETYK PSO-1 and PSO-2 of deucravacitinib, focused on treating moderate-to-severe psoriasis. The findings will be presented during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX). Investors and the public can access the live webcast and materials at investor.bms.com, with an archived version available later the same day.

Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Friday, April 23, 2021 at 10:30 a.m. ET to discuss data from the POETYK PSO-1 and POETYK PSO-2 Phase 3 trials of deucravacitinib in patients with moderate-to-severe psoriasis, which will be presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX).

Company executives will provide an overview of data presented and address questions from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the event at http://investor.bms.com. Materials related to the webcast will be available at the same website prior to the event. An archived edition of the Investor Event will be available later that day.

About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

CorporateFinancial-News

View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005111/en/

FAQ

What is the date and time of the Bristol Myers Squibb virtual Investor Event?

The Bristol Myers Squibb virtual Investor Event is scheduled for April 23, 2021, at 10:30 a.m. ET.

What will be discussed during the Bristol Myers Squibb Investor Event?

The event will discuss data from the POETYK PSO-1 and POETYK PSO-2 Phase 3 trials of deucravacitinib for moderate-to-severe psoriasis.

Where can I watch the Bristol Myers Squibb Investor Event?

You can watch the Bristol Myers Squibb Investor Event live at investor.bms.com.

Will there be an archived version of the Investor Event?

Yes, an archived edition of the Bristol Myers Squibb Investor Event will be available later that day.

What are the POETYK PSO-1 and POETYK PSO-2 trials about?

The POETYK PSO-1 and POETYK PSO-2 trials evaluate the efficacy of deucravacitinib in patients with moderate-to-severe psoriasis.